Alkido Pharma Quote - AIKI | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Alkido Pharma Inc (AIKI) Share Price

Alkido Pharma Inc (AIKI)

3.56

0.00

(0.00%)

Closed 05 October 7:00AM

Delayed by 15 minutes

0.00

0.00

(0.00%)

After Hours: -

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

3.56

Bid

3.53

Offer

3.98

Volume

-

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

3.56

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

-

Shares Outstanding

5,345,000

Dividend Yield

-

PE Ratio

-0.38

Earnings Per Share (EPS)

-4.28

Revenue

2.04M

Net Profit

-22.88M

AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin... AIkido Pharma Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing a antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Show more

Sector

Security Brokers & Dealers

Industry

Security Brokers & Dealers

Website

www.dominariholdings.com

Headquarters

Wilmington, Delaware, USA

Founded

-

Dominari Securities CEO, Kyle Wool, Discusses the IPO Market on "The Claman Countdown"

Dominari Securities CEO, Kyle Wool, Discusses the IPO Market on "The Claman Countdown" PR Newswire NEW YORK, June 21, 2023 NEW YORK, June 21, 2023 /PRNewswire/ -- Dominari Holdings Inc...

Dominari Holdings Appoints George Way Chief Financial Officer

Dominari Holdings Appoints George Way Chief Financial Officer PR Newswire NEW YORK, April 3, 2023 Experienced Finance Executive to Support Growth Strategy NEW YORK, April 3, 2023 /PRNewswire/...

Dominari Holdings Provides Update on Share Repurchase Program

Dominari Holdings Provides Update on Share Repurchase Program PR Newswire NEW YORK, Feb. 24, 2023 NEW YORK, Feb. 24, 2023 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the...

Dominari Holdings Provides Update on Share Repurchase Program

Dominari Holdings Provides Update on Share Repurchase Program PR Newswire NEW YORK, Dec. 28, 2022 NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the...

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH) PR Newswire NEW YORK, Dec. 22, 2022 NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma...

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes PR Newswire NEW YORK, Nov. 28, 2022 Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW...

AIkido Share Repurchase Continues

AIkido Share Repurchase Continues PR Newswire NEW YORK, Oct. 6, 2022 NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update...

AIkido Purchases More Shares

AIkido Purchases More Shares PR Newswire NEW YORK, Oct. 5, 2022 NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on...

Share Repurchase Program Continues

Share Repurchase Program Continues PR Newswire NEW YORK, Oct. 4, 2022 NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update...

AIkido Pharma Continues Share Repurchase Program

AIkido Pharma Continues Share Repurchase Program PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CHSNChanson International Holding	US$ 11.22 (269.08%)	14.76M
PEVPhoenix Motor Inc	US$ 1.0607 (205.24%)	228.42M
ENTOEntero Therapeutics Inc	US$ 0.60 (72.20%)	10.42M
BENFBeneficient	US$ 1.8914 (58.94%)	108.31M
FORDForward Industries Inc	US$ 5.3254 (52.15%)	18.45M
ADDColor Star Technology Company Ltd	US$ 0.2701 (-39.98%)	15.01M
DUOFangDD Network Group Ltd	US$ 2.53 (-32.89%)	28.52M
ICCTiCoreConnect Inc	US$ 0.4102 (-31.50%)	1.68M
ZENAZenaTech Inc	US$ 3.91 (-29.55%)	213.24k
SPAISafe Pro Group Inc	US$ 1.93 (-25.77%)	239.89k
NVDANVIDIA Corporation	US$ 124.92 (1.68%)	244.46M
PEVPhoenix Motor Inc	US$ 1.0607 (205.24%)	228.42M
SQQQProShares UltraPro Short QQQ	US$ 7.43 (-3.63%)	184.47M
NCNCnoco noco Inc	US$ 0.144 (8.60%)	147.38M
BENFBeneficient	US$ 1.8914 (58.94%)	108.31M

Viewmont

Viewmont 2 years ago

Viewmont

Viewmont 2 years ago

Hi, I haven't been following AIKI for a while, just noticed its not trading, checked TDA / google with no result, did the ticker change or not public anymore after company bought shares? Thanks!

db101

db101 2 years ago

More insider shares purchased today…

db101

db101 2 years ago

More insider shares purchased…

db101

db101 2 years ago

AIKI looks to be headed back to 7…

db101

db101 2 years ago

More insider shares purchased…

db101

db101 2 years ago

A positive week… up 3.11%

db101

db101 2 years ago

…more shares purchased by the CEO

db101

db101 2 years ago

…AIKI seems to be getting its legs

db101

db101 2 years ago

AIKI is undervalued…

db101

db101 2 years ago

AIKI is ready…

db101

db101 2 years ago

The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.

db101

db101 2 years ago

The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."

db101

db101 2 years ago

AIKI is buying more shares… 45k

ANTI-BAGHOLDER

ANTI-BAGHOLDER 2 years ago

Shalom Auerbach board member on AMRR doesn’t mess around.

Shalom Auerbach, a significant stockholder of AIkido Pharma Inc. (NASDAQ: AIKI) beneficially owning approximately 3.4% of its common stock, today issued the following letter to members of the AIkido Pharma Inc. Board of Directors:

https://www.streetinsider.com/dr/news.php?id=20187179&gfv=1

PStockPickz

PStockPickz 3 years ago

https://www.prnewswire.com/news-releases/aikido-pharma-secures-interest-in-electric-truck-maker-tevva-motors-ltd-301386841.html

PStockPickz

PStockPickz 3 years ago

Averaging in some .48s

PStockPickz

PStockPickz 3 years ago

Snagging some 50s

RNsidersbuying

RNsidersbuying 3 years ago

AIkido Pharma announces $3M share repurchase program

https://ih.advfn.com/stock-market/NASDAQ/alkido-pharma-AIKI/stock-news/87087386/aikido-pharma-announces-3m-share-repurchase-progr

urge2surge

urge2surge 3 years ago

Classic dog pile here. I'm out and won't be back.

RNsidersbuying

RNsidersbuying 3 years ago

AIKI .47 - So, outsiders have sold this company's stock down to less than .50-on-the-dollar and insiders aren't filing Form-4-Buys by the truckload? How can management EVER promote it's own stock again when they show no interest in less than .50-on-the-dollar?

And what would be management's risk be in buying here at less than .50-on-the-dollar? It goes down to .25-on-the-dollar...whoa-is-me

urge2surge

urge2surge 3 years ago

One of the worst companies I've invested in. Finally dumped it for big loss. I obviously played the fool again. Glta

georgie18

georgie18 3 years ago

AIKI...72...:partying_face:

db101

db101 3 years ago

Get ready for the buttered popcorn...

georgie18

georgie18 3 years ago

AIKI...73...Bullish 3 Gap Downs Reversal Pattern to the Upside on this Oversold Chart...

Psar flipped Bullish...Been accumulating under $1...

Chart https://schrts.co/exhPMSRA ...

White Lightning

White Lightning 3 years ago

Looks like good news AlKl

https://apple.news/AnumIdrGsR-CRYxMFTxj-5Q

This should go over a dollar soon here!!!!

TheFinalCD

TheFinalCD 3 years ago

AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 added to AIKI balance sheet. $AIKI

AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 added to AIKI balance sheet. $AIKI— Tommy Coops (@ohheytommy) October 12, 2021

georgie18

georgie18 3 years ago

AIKI...92...on the P/M Gappa...:partying_face:

urge2surge

urge2surge 3 years ago

Impressed with the CEO management taking investment stakes in pivotal companies, thereby adding significant value here. Great job IMO.

TGOO

TGOO 3 years ago

Interesting, low ss here...

Sirpeter

Sirpeter 3 years ago

Very volatile but looks ready

sportd

sportd 3 years ago

Added let’s see what this can do

Sirpeter

Sirpeter 3 years ago

Sirpeter

Sirpeter 3 years ago

antman

antman 3 years ago

Would be nice... it has been ages since they did the financing around $1.65 and it began to drop ever since

db101

db101 3 years ago

AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

db101

db101 3 years ago

georgie18

georgie18 3 years ago

AIKI...86...Tue, July 27, 2021, 10:00 AM
AIkido's License to Technology Includes Targeted Psilocybin Treatment for Cancer Patients

NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125. This technology relates to the use of novel and proprietary central nervous system (CNS) homing peptides. This technology has been exclusively sublicensed to AIkido Pharma for use of psilocybin for the therapeutic treatment of neuroinflammatory disease in cancer patients.

georgie18

georgie18 3 years ago

AIKI...97...Bounce off the .85 range on the Bullish Engulfing Reversal Candle to the Upside...

Psar flipped to a Bullish Buy Position...as the MACD Crossed to the positive side...

Chart...https://schrts.co/FqVVQIHY ...

wesley_

wesley_ 3 years ago

urge2surge

urge2surge 3 years ago

No respect from the street on this company. Corporate..how about getting some dignity and respect by actually executing and aggressive communications to the investing arena? Grow a pair..

urge2surge

urge2surge 3 years ago

Yeah definitely under substantial book value here. Not just on cash, but potential pipeline, nols, licensing rev's. You buy the dips here and wait on a significant return.

Chess Master

Chess Master 3 years ago

BULLISH RESEARCH ARTICLE! Trading under cash and great upside on great results. https://insiderfinancial.com/akido-pharmas-aiki-clinical-trial-results-continues-to-validates-gileads-21-billion-purchase-of-immunomedics/181580/

ClayTrader

ClayTrader 3 years ago

* * $AIKI Video Chart 04-21-2021 * *

Link to Video - click here to watch the technical chart video

georgie18

georgie18 3 years ago

AIKI...86...NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.

The article can be accessed at:
https://www.thepharmaletter.com/article/further-vindication-for-novartis-in-radioligand-space

georgie18

georgie18 3 years ago

AIKI...$1.20...in the P/M...NEW YORK, April 7, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it has been granted an exclusive sublicense to technology related to the use of novel and proprietary central nervous system (CNS) homing peptides for the therapeutic treatment of neuroinflammatory disease in cancer patients...

https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1857821

georgie18

georgie18 4 years ago

AIKI...$1.17...Bidding the Lower Band to the 20ma to add to my Core Position...

Looking for the 2 Open Gaps to fill and a $2 Breakout..imo...we shall see....

Chart...https://schrts.co/BrjKBXYy ...

georgie18

georgie18 4 years ago

AIKI...$1.17...in the P/M...https://www.otcmarkets.com/stock/AIKI/news/story?e&id=1849940 ...:party:

Taurus69

Taurus69 4 years ago

$aiki $1.17 ? 0.0 (0.00%)
Volume: 3,920,435 @03/26/21 7:41:58 PM EDT

ClayTrader

ClayTrader 4 years ago

* * $AIKI Video Chart 03-24-2021 * *

Link to Video - click here to watch the technical chart video

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions